Drug intelligence / Profile preview

CYD dengue vaccine

Development stage: Unknown
Lead developer: Sanofi Pasteur
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Subcutaneous

Overview

CYD dengue vaccine is a tetravalent live-attenuated recombinant vaccine developed by Sanofi Pasteur. It is designed to prevent symptomatic virologically-confirmed dengue cases by eliciting an immune response against all four dengue virus serotypes (1, 2, 3, and 4). The vaccine has been studied in various dose schedules and booster regimens to assess its immunogenicity and safety in healthy subjects across different age groups and geographical regions.

Other names: ChimeriVax Tetravalent Dengue Vaccine

Beyond the preview

Go deeper on CYD dengue vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CYD dengue vaccine.

Explore the full profile